You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria
|
|---|---|
| Published in |
Clinical and Translational Allergy, February 2017
|
| DOI | 10.1186/s13601-017-0141-3 |
| Pubmed ID | |
| Authors |
Mignon T. van den Elzen, Harmieke van Os-Medendorp, Imke van den Brink, Karin van den Hurk, Ouliana I. Kouznetsova, Alexander S. H. J. Lokin, Anna-Marijke Laheij-de Boer, Heike Röckmann, Carla A. F. M. Bruijnzeel-Koomen, André C. Knulst |
| Abstract |
Treatment with second-generation antihistamines is recommended in patients with chronic spontaneous urticaria (CSU). Some patients remain unresponsive even after up-dosing up to fourfold. Many third line treatment options have limited availability and/or give rise to significant side effects. We investigated effectiveness and safety of antihistamine treatment with dosages up to fourfold and higher. This retrospective analysis of patients' records was performed in adult CSU patients suffering wheals and/or angioedema (AE). Demographic, clinical, and therapeutic data was extracted from their medical records. We recorded the type, maximum prescribed dosage, effectiveness, and reported side effects of antihistamine treatment. Of 200 screened patients, 178 were included. Treatment was commenced with a once daily dose of antihistamines. Persisting symptoms meant that up-dosing up to fourfold occurred in 138 (78%) of patients, yielding sufficient response in 41 (23%). Up-dosing antihistamines was necessary in 110 (80%) patient with weals alone or weals with angioedema and 28 (64%) with AE only (p = 0.039). Of the remaining 97 patients with insufficient response, 59 were treated with dosages higher than fourfold (median dosage 8, range 5-12). This was sufficient in 29 patients (49%). Side effects were reported in 36 patients (20%), whereof 30 (17%) experienced somnolence. Side effects after up-dosing higher than fourfold were reported in six out of 59 patients (10%). Up-dosing antihistamines higher than fourfold dosage seems a feasible therapeutic option with regards to effectiveness and safety. The need for third line therapies could be decreased by 49%, with a very limited increase of reported side effects. |
X Demographics
The data shown below were collected from the profiles of 48 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 10 | 21% |
| United Kingdom | 6 | 13% |
| United States | 5 | 10% |
| Romania | 4 | 8% |
| Sweden | 1 | 2% |
| Panama | 1 | 2% |
| United Arab Emirates | 1 | 2% |
| Canada | 1 | 2% |
| Austria | 1 | 2% |
| Other | 6 | 13% |
| Unknown | 12 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 32 | 67% |
| Practitioners (doctors, other healthcare professionals) | 8 | 17% |
| Scientists | 6 | 13% |
| Science communicators (journalists, bloggers, editors) | 2 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 20% |
| Student > Bachelor | 6 | 12% |
| Unspecified | 3 | 6% |
| Student > Ph. D. Student | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 19 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 30% |
| Unspecified | 3 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Neuroscience | 2 | 4% |
| Nursing and Health Professions | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 22 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 45. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2023.
All research outputs
#944,351
of 25,744,802 outputs
Outputs from Clinical and Translational Allergy
#19
of 767 outputs
Outputs of similar age
#21,053
of 435,995 outputs
Outputs of similar age from Clinical and Translational Allergy
#2
of 11 outputs
Altmetric has tracked 25,744,802 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 767 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,995 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.